Unlike natural antibodies, single-chain Fv (sFv) proteins normally lack asparagine-linked glycosylation. Many designed immunoconjugates and other therapeutics currently employ the advantageous conjugation chemistry or targeting properties provided by the glycoprotein oligosaccharide domain. sFv proteins with engineered N-glycan designs were evaluated in Pichia pastoris for glycosylation efficiency, expression level, oligosaccharide chain length and composition, and affinity. In contrast to nearly all natural glycoproteins, the engineered attachment of Nglycans conveniently near the polypeptide C-terminus was found to produce the optimal results. Furthermore, the percentage modification and chain length of the attached mannose chains were controllable by the use of tandem and overlapping Asn-X-Thr tripeptide sites. The glycosylated sFv mannose chains could be effectively conjugated to polyethylene glycol and the resulting conjugate displayed a 10-fold increased circulating life in mice. The potential to control polymer:sFv or drug:sFv molar ratios by sitespecific conjugation may substantially improve the therapeutic efficacy of these minimal antigen-binding molecules.
Introduction
The engineering advantages provided by the single gene, single polypeptide design of single-chain Fv proteins have increasingly made sFv proteins the antigen-binding format of choice for antibody engineers (Begent et al., 1996; Fearon, 1997; Hoogenboom, 1997) . More recently, there have been several engineering advances which attempt to combine the effector, avidity or pharmacological properties of intact monoclonal antibodies with the simplicity of sFv proteins (Whitlow et al., 1994; Filpula et al., 1996; Holliger et al., 1997; Kontermann et al., 1997) . For example, multivalency may be engineered in multimeric sFv. The normal effector functions of whole antibodies may be either attached in sFv/Fc fusion proteins or recruited by bifunctional sFv molecules. Pharmacological properties such as circulating half-life are similarly influenced by sFv protein formats. Meanwhile, the affinity maturation of natural antibodies by somatic mutation has been surpassed by in vitro CDR mutagenesis and phage display methods that have produced high affinity specificities to virtually any antigen (Marks and Marks, 1996) .
Another property of natural IgG antibodies which has been useful in the development of immunoconjugates is the presence of N-linked glycosylation on the CH 2 domain. The oligosacch-aride chains of IgG have been preferred conjugation sites for drugs and other molecules in the development of antibody based therapeutics (Rodwell et al., 1986; Leung et al., 1995) . Beyond immunoglobulins, protein glycosylation is often a critical factor in determining pharmacokinetics and biodistribution. For example, mannose-terminated proteins or drugs may be targeted to cells of the reticuloendothelial system (Seymour, 1994) . N-Linked glycosylations have been reported to occur sporadically at non-conserved positions within the framework on hypervariable regions of several natural antibodies and may influence antigen-binding properties (Wright and Morrison, 1997) . However, the use of glycosylated sFv proteins as therapeutic agents will only be of practical application if it meets the following criteria. First, the glyco-sFv must be expressed in high yield, and preferably secreted from a microbe. Second, the oligosaccharide attachment events must be efficient such that little unmodified sFv is produced. Third, sFv antigenbinding affinity should be preserved and the N-linked site should be distal to the antigen-binding site. Fourth, the attached oligosaccharide should be relatively homogeneous and have a composition suitable for conjugation or biological recognition processes. Fifth, the chain length of the oligosaccharides should ideally be adjustable to provide versatility in design.
Using the model single-chain Fv, CC49/218 sFv, we have engineered glyco-sFv proteins expressed from the yeast Pichia pastoris which meet each of these criteria. High-level expression of unmodified sFv in P.pastoris has been reported previously (Ridder et al., 1995; Eldin et al., 1997; Luo et al., 1997) . Surprisingly, attachment of N-linked core glycosylation very near the C-terminus proved to be the most desirable overall strategy. Further, our unexpected discovery that tandem and overlapping N-X-T sequons resulted in the appearance of extended mannose chains provided glyco-sFv molecules with multiple potential conjugation sites for polymers and drugs at positions which are both diametrically opposed to the antigen-binding site and physically removed from the Fv architecture.
Materials and methods

Materials
The gene for CC49/218 sFv was obtained from the Enzon plasmid pGX5608. The complete DNA sequence of CC49/ 218 sFv has been reported (Filpula et al., 1996) .
Oligonucleotides were synthesized using a Millipore Cyclone DNA Synthesizer. Invitrogen (San Diego, CA) supplied P.pastoris hosts and vectors. The GlycoTrack Carbohydrate Detection Kit, Endo-glycosidase H, Peptide-N-glycosidase F, α-mannosidase (jack bean), α-mannosidase (Aspergillus saitoi) and β-mannosidase were purchased from Oxford GlycoSystems (Rosedale, NY). Digoxigenin-labeled lectin GNA was obtained from Boehringer Mannheim (Indianapolis, IN). Precast polyacrylamide slab gels (4-20%) were obtained from Novex (San Diego, CA). Bovine submaxillary mucin type I was purchased from Sigma (St Louis, MO). Superdex 75 and C-terminus:  EN225  ---svtvs  EN235, EN236  ---svtvsNKTS  EN279  ---svtvsNKTNATS  EN280  ---svtvsNKTNNTTS  EN292  ---svtvsNKTSGSTS  EN293  ---svtvsNKTNATNATS  EN294 ---svtvsSKTNNTTS 218 linker:
---gstsgsgkpNKTNNTTNKTNNTTgsgegstkg---a NXT tripeptides in bold; 218 linker and V H in lower case. The svtvs V H terminal sequence includes V H residues 108-112 (Filpula et al., 1996) .
Con A Sepharose were obtained from Pharmacia Biotech (Piscataway, NJ). POROS HS was purchased from PerSeptive Biosystems (Framingham, MA). Purified CC49/218 sFv protein derived from Escherichia coli GX9251 was obtained from Enzon. Rabbit anti-CC49/218 sFv polyclonal antibody was obtained from HRP (Denver, PA). Mouse anti-CC49/218 polyclonal antibody and PEG5000-hydrazide were obtained from Enzon.
sFv gene constructions
The CC49/218 sFv gene from plasmid pGX5608 was modified by oligonucleotide-directed mutagenesis using the procedure of Ho et al. (1989) . The designed changes for N-linked glycosylation (N-X-T/S) are indicated in Table I or described in the text. DNA sequence analysis using T7 Sequenase version 2.0 (Amersham) was performed to confirm the correct constructions. For the final construction of the EN225 sFv gene which is ligatable as an EcoRI-BamHI fragment to P.pastoris vector pHIL-S1 (Invitrogen), the primer pair 5Ј-CGGAATTCGACGTCGTGATGTCACAG-3Ј and 5Ј-GC-AACCGAGCGTTCTGA-3Ј were used in a PCR reaction. The existing BamHI site in pGX5608 was conserved in this reaction.
Glyco-sFv gene constructions
Glyco-sFv genes encoding C-terminal extensions were prepared in analogous PCR reactions for ligation into pHIL-S1. The downstream primers were 5Ј-CCAGGATCCTATTAAC-TGGTCTTGTTGGAGACGGTGACTGA-3Ј (EN235), 5Ј-CC-GGGATCCTATTAAGAGGTAGCATTGGTCTTGTTGGAG-ACGGTG-3Ј (EN279), 5Ј-CCGGGATCCTTAAGAGGTAG-TATTGTTGGTCTTGTTGGAGACGGTG-3Ј (EN280), 5Ј-CTCGGGATCCTATTAAGAGGTGGAACCAGAGGTCTT-GTTGGAGAC-3Ј (EN292), 5Ј-CTCGGGATCCTATTAAG-AAGTGGCATTGGTAGCATTGGTCTT-3Ј (EN293) and 5Ј-GATCGGATCCTTAAGAGGTAGTATTGTTGGTCTTAGA-GGAGACGGTGACTGA-3Ј (EN294). Glyco-sFv genes encoding insertions in the SmaI site of the 218 linker were prepared by a single ligation (EN290) or a tandem ligation (EN291) of the synthetic linker pair 5Ј-AACAAGACCAA-CAATACTACC-3Ј and 5Ј-GGTAGTATTGTTGGTCTTGTT-3Ј. Single N-X-T sequons were introduced at other sites using site-directed mutagenesis.
Expression of glyco-sFv in Pichia pastoris
The P.pastoris expression vector pHIL-S1 was used for expression of both the unmodified and glycosylated sFv. This vector provides a signal sequence derived from the yeast gene PHO1 which is fused to the CC49/218 sFv and glyco-sFv genes at the EcoRI site. After signal processing, the N-terminal sequence of the sFv proteins is REFD---, where the normal N-terminal D residue is preceded by three amino acids. The cloning and expression procedures for production of sFv from Pichia were carried out as described in the 'Pichia Expression Kit Instruction Manual' from Invitrogen. Transformation of P.pastoris GS115 with the pHIL-S1/sFv vectors was performed by the spheroplast transformation procedure followed by screening of His ϩ and Mut S phenotypes. The transformants were grown in 10 ml of BMGY medium for 48 h at 30°C using a shaking (250 r.p.m.) incubator. Subsequently, the methanol-induced cultures were grown for 48 h in BMMY medium at 30°C and the culture supernatants were collected following centrifugation. The secretion of sFv and glyco-sFv proteins using the alternate expression vectors pIC9 and pHIL-S1 produced similar yields and glycosylation efficiency when directly compared for variant EN279. SDS-PAGE analysis SDS-PAGE was performed using pre-cast 4-20% slab gels from Novex. Protein bands were visualized by staining with Coomassie Brilliant Blue G-250. Area quantitation of stained bands from culture supernatants, standard proteins and purified glyco-sFv proteins, before and after N-glycanase digestion, was performed using a Molecular Dynamics PD-SI laser scanner.
Western blot analysis
Immunoblotting procedures for transfer of proteins from polyacrylamide gels to nitrocellulose membranes by the semi-dry method were performed as described by Harlow and Lane (1988) . Briefly, the blotted membranes were blocked in PBS containing 1% BSA (blocking solution) at 22°C for 2 h, washed three times with PBS and incubated with a 1:1000 dilution of rabbit anti-CC49/218 sFv antibody in blocking solution at 4°C overnight. Next, a 1:1000 dilution of horseradish peroxidase-conjugated goat anti-rabbit IgG in blocking solution was used in a 1 h incubation at 22°C. After washing with PBS, the membranes were developed with TMBM-500 (MOSS) at room temperature for 1 min.
Purification of glyco-sFv proteins
An adaptation of our reported protocols for purification of CC49/218 sFv from E.coli was used (Filpula et al., 1996) . Two liters of culture medium were concentrated to 80 ml by diafiltration. The concentrate was chromatographed on a 60 ϫ 2 cm i.d. Superdex 75 size-exclusion column equilibrated in 15 mM Tris-HCl (pH 6.2). Fractions having mucin-binding activity were collected and loaded on a 7 ϫ 2 cm i.d. POROS-HS cation-exchange column equilibrated in 15 mM Tris-HCl (pH 6.2). Glyco-sFv was eluted with 15 mM Tris-HCl (pH 6.2) containing a gradient of 0-150 mM NaCl. The isolated fractions were further purified by Superdex 75 SE chromatography to isolate specific high molecular weight glyco-sFv fractions.
Endoglycosidase and exoglycosidase digestions
Peptide-N-glycosidase F, Endo-glycosidase H, jack bean α-mannosidase, Aspergillus α-mannosidase and β-mannosidase were obtained from Oxford GlycoSystems and used according to the accompanying product literature.
Glycoprotein staining
The GlycoTrack carbohydrate detection kit (Oxford GlycoSystems) was used according to the manufacturer's instructions.
Digoxigenin-labeled Galanthus nivalis lectin GNA was used according to the supplier's instructions (Boehringer Mannheim).
Binding of glyco-sFv to Con A Sepharose A 1 ml amount of Con A Sepharose resin in binding buffer (20 mM Tris-HCl, pH 7.4, 0.5 M NaCl) was incubated with 50 µl of dialyzed EN235 culture supernatant. The beads were pelleted by microcentrifugation and the supernatant was removed. Elution the bound glyco-sFv was performed by washing the resin with binding buffer containing 0.2 M α-D-methylmannoside.
ELISA for sFv binding activity
Immunoassay procedures were performed using modifications of previously published protocols (Milenic et al., 1991; Whitlow et al., 1994) . Bovine submaxillary mucin (250 ng per 100 µl well) antigen was used to coat microtiter plate wells (MaxiSorp, Nunc, VWR Scientific, Boston, MA). The glyco-sFv or purified CC49/218 sFv proteins were diluted serially in PBS containing 1% BSA and incubated in the coated wells at 22°C for 1 h. After the plate had been washed with PBS containing 0.05% Tween 20 (PBS-T), the bound sFv was detected by a 1 h incubation with a secondary antibody (mouse anti-CC49/218), followed by a PBS-T wash and a 1 h incubation with an alkaline phosphatase-conjugated rabbit antimouse IgG antibody. Signal generation was performed using PNPP a described by Harlow and Lane (1988) . The plate was read at 405 nm using a Molecular Devices (Sunnyvale, CA) plate reader. In a second ELISA method, rabbit anti-CC49/ 218 sFv (1:2000 dilution) and HRP-conjugated goat anti-rabbit serum (1:2000 dilution) were successively incubated at 37°C for 1 h. The plates were washed three times with PBS-T and were read at 650 nm following addition of 100 µl of 3Ј,3Ј,5Ј,5Ј-tetramethylbenzidine (TMB).
Competition ELISA
The apparent affinity constants (K d ) of the glyco-sFv variants were determined using biotin-labeled CC49/218 sFv in competition immunoassays as reported previously (Milenic et al., 1991; Whitlow et al., 1994) .
PEGylation of glyco-sFv
Purified glyco-sFv was oxidized with sodium periodate, conjugated to PEG5000-hydrazide and reduced with NaCNBH 3 as described previously (Zalipsky et al., 1997) . Polyethylene glycol-conjugated glyco-sFv was purified by size-exclusion HPLC.
Circulating life in mice
Pharmacokinetics of sFv and sFv conjugates were measured in ICR (CD-1) 7-8-week-old female mice supplied by Harlan Sprague Dawley (Madison, WI). A single intravenous injection of 60 µg of glyco-sFv protein was performed via the tail vein. After compound administration, sampling of blood (100 µl) via the recta orbital sinus was undertaken following anesthetization with 0.09% Avertine. Blood was allowed to clot and then processed for serum and immediately frozen. The concentrations of the modified sFv were measured by ELISA. The circulatory half-life, area under the curve and mean residence time for the sFv proteins were calculated using a one-compartment i.v. bolus model (WinNonlin software package, Scientific Consulting, Apex, NC). The correlation between the observed and predicted model time point values was ജ95%. 
Results
Design strategy for glyco-sFv
A structural view of V L -linker-V H sFv architecture (Whitlow et al., 1993 (Whitlow et al., , 1995 ) and a consensus model of N-glycan highmannose structures in P.pastoris (Kukuruzinska et al., 1987; Herscovics and Orlean, 1993; Miele et al., 1997) are shown in Figure 1A and B, respectively. The anti-TAG-72 sFv protein CC49/218 (Milenic et al., 1991) , which was recently investigated clinically as an imaging agent for metastatic colorectal carcinoma (Larson et al., 1997) , was chosen as a model sFv for our investigations of N-linked glycosylations in P.pastoris. Expression of the CC49/218 sFv gene using the vector pHIL-S1 produced correctly processed, secreted sFv protein at about 30-70 mg/l per gene copy number. The CC49/ 218 sFv purified from P.pastoris EN225 and the clinical-grade sFv from E.coli GX9251 were found to have equivalent affinity (K d ϭ 3.6 ϫ 10 -9 M). In order to minimize the potential for N-linked glycans to block sterically the antigen-binding site, our preferred N-linked attachments were initially placed in four back loop residues V L 12, V L 77, V H 13 and V H 82B (Kabat et al., 1991) , the second residue of the 218 linker or the Cterminus. Site-directed mutagenesis of one or two codons introduced the tripeptide sequon at each of these locations. However, we found that placement of one N-X-T/S site at these positions resulted in either inefficient glycosylation or poor expression. Likewise, combination of five or six of these tripeptide sites within one variant protein yielded detectable modifications, but poor yields and heterogeneous products. The best initial results were obtained with the V H C-terminal modification (EN235) which placed the N-X-T sequon one residue before the terminal serine (see Table I ). In this case, as much as 55% of the expressed sFv contained N-linked core glycan of~3 kDa as characterized by SDS-PAGE and Western blot analysis using the N-glycanases Endo-H and PNGFase. However, the placement of the single N-X-T tripeptide before a five-residue C-terminal extension (EN292) increased the efficiency of core N-glycan addition to Ͼ95% modification (see Table I and Figure 2A ). EN292 shake-flask culture expression yields of 70-100 mg/l surpassed those of native EN225 sFv and affinities were not reduced for these purified glyco-sFv proteins. Since the presence of an N-glycan within 4-8 residues of the C-terminus is extremely rare in natural glycoproteins (Gavel et al., 1990) , this was an unexpected result and encouraged us to investigate another rarity in N-glycosylation: the use of tandem or overlapping N-X-T tripeptide sites.
C-Terminal tandem and overlapping sites
Two and three tandem tripeptide sites of the sequence [N-X-T] n or the overlapping design N-N-T-T were investigated either at the sFv C-terminus or within the 218 linker (see Table I ). The inclusion of three tripeptide sites (two of which are overlapping) in the C-terminal construction, EN280, resulted in essentially complete sFv modification with undetectable amounts of native sFv as analyzed by Western blots (see Figure 2A ). More remarkably, the inclusion of tandem sites was found to induce a form of hyperglycosylation resulting in N-glycan molecular masses of 9-15 kDa as estimated by SDS-PAGE analysis. EN279 (two tandem sites) displays both core modification and extended chain forms. All glyco-sFv variants were quantitatively converted to the native sFv polypeptide by Endo-H or PNGase F N-glycanase digestions (see Figure  3A) . We found that the three-site tandem variant EN293 produced exclusively hyperglycosylated sFv whereas the EN280 products also contained detectable 6 kDa N-glycan products. Perhaps the most surprising result is shown in Figure  2A for EN294. Inclusion of the single two-site overlapping tripeptide sequence N-N-T-T one residue before the Cterminal serine produced glyco-sFv products whose N-glycan molecular mass corresponded to~3 kDa (minor) and 9-15 kDa (major). By Western blot analysis, unmodified sFv was not detectable in the EN294 culture. In contrast, the corresponding one-site version, EN292, produces exclusively glyco-sFv with a 3 kDa core N-glycan when examined by Coomassie Blue stained SDS-PAGE gels. This delineates a minimal signal (NNTT) for one form of hyperglycosylation in Pichia. Of the C-terminal glyco-sFv variants examined, lowered expression (~5-10 mg/l) was observed only in EN293. From these empirical results, the practical choice of production of either core N-glycan modified sFv (EN292) or hyperglycosylated sFv (EN280) is achievable with high yields of secreted glyco-sFv (Ͼ50 mg/l).
Linker tandem and overlapping sites
Inclusion of tandem or overlapping sites at other sFv designed sites was also successful in promoting increased core glycosyla- 4 . ELISA of glyco-sFv culture supernatants from P.pastoris transformants expressing mucin-binding activity. The parent strain GS115, CC49/218 sFv purified from E.coli GX9251, and BSA (10 mg/ml) were included as controls. Each starting sFv sample (~50 µg/ml) was analyzed in 1:2 serial dilutions.
tion and/or hyperglycosylation. For example, CC49 sFv with three tandem sequons inserted in the 218 linker produced products containing unmodified, core-modified and hyperglycosylated sFv (see Figure 2B ). Although these linker modified proteins maintain mucin-binding specificity, expression (secretion) yields were diminished. Indeed, expression of the six tandem NXT linker variant, EN291, produced nearly undetectable yields. The choice of a C-terminal modification seems to be the optimal design by all criteria in our studies. Affinity constants of glyco-sFv N-linked glycosylation of CC49/218 sFv did not significantly affect the binding affinity of the protein as characterized by ELISA or competition ELISA. Figure 4 shows serial dilutions of the dialyzed glyco-sFv and native sFv supernatants analyzed for mucin-binding activity. When the corresponding purified proteins were analyzed by competition ELISA, the greatest difference in apparent affinity was found between the EN225 native sFv (K d ϭ 3.6 ϫ 10 -9 M) and the EN280 three-site glyco-sFv (K d ϭ 7.3 ϫ 10 -9 M).
Characterization of N-glycans
Unlike mammalian N-glycans, yeast N-linked oligosaccharides have a relatively simple 'high-mannose' structure (Herscovics and Orlean, 1993; Miele et al., 1997) . Pichia N-glycans may be even less complex than those of Saccharomyces cerevisiae in that the potentially immunogenic α1-3 mannose extensions have not been reported. Typical core glycosylation with Man 8-14 GlcNAc 2 may be further modified by α1-6 mannose outer chains which may have α1-2 mannose branches (see Figure 1B) . However, while 'hypermannosylation' is typical in S.cerevisiae, these extended mannose chains are not commonly observed in heterologous expression of glycoproteins in P.pastoris (Cregg et al., 1993) . We investigated whether the core glycosylated and hyperglycosylated sFv proteins conform to this structure by digestion with Endo-H, PNGase F, β-mannosidase, Aspergillus α1-2,3 mannosidase and jack bean α1-2,6Ͼ3 mannosidase. As shown in Figure 3A , all N-glycans were quantitatively removed by N-glycanase Endo-H digestion. PNGase F digestion produced similar results (data not shown). Furthermore, digestion with the jack bean mannosidase, but not the β-or α-1-2,3 mannosidase, quantitatively converted the sFv core N-glycans to a glycoprotein of reduced molecular mass (see Figure 3B and C). Hyperglycosylated sFv is partially digested by jack bean mannosidase to produce glyco-sFv of reduced and more homogeneous size (see Figure 3C ). These data are consistent with previous reports which indicate that Pichia N-linked glycans have a high-mannose composition. All glyco-sFv proteins could be visualized by the GlycoTrack glycosylation detection method. In addition, digoxigeninlabeled lectin GNA, which recognizes terminal mannose residues of glycoproteins, specifically detected each glyco-sFv form in modified Western blots (unpublished data). Con A Sepharose quantitatively separated EN235 unmodified sFv (27 kDa) from the glyco-sFv (30 kDa), which was bound and then eluted by α-D-methylmannoside, as shown in Figure  3D . This is consistent with the α-D-mannopyranosyl binding properties of this lectin. A complete linkage analysis is necessary to fully define the oligosaccharides. However, the N-glycan molecular masses (see Figures 2A and 3A) conform to the expected structures from yeast for a core N-glycan of 3 kDa, two core N-glycans of~6 kDa and extended outer chains with more than 50 mannose residues of~9-15 kDa.
Purification and PEGylation of glyco-sFv
The glyco-sFv proteins were purified by ion-exchange chromatography and size-exclusion HPLC. In order to evaluate the feasibility of using glycosylated sFv in bioconjugate applications, we covalently modified the oligosaccharide chains of the glyco-sFv EN280 with hydrazide-activated polyethylene glycol 5000 (PEG-5000) (Zalipsky and Menon-Rudolph, 1997) . The PEGylated product was purified by ion-exchange and size-exclusion HPLC. Unmodified glyco-sFv was completely removed and the approximate PEG:sFv molar ratio was calculated as 3-4 PEG polymers per sFv in the purified fraction used for subsequent in vivo studies. The apparent affinity constant of the PEGylated protein was reduced about 6-fold compared with EN280. This may be the result of suboptimal reaction conditions and/or the effect of steric hindrance of the antigen-binding site by the PEG polymers in the competition ELISA. However, as a result of an enhanced circulating life and reduced immunogenicity, PEGylated proteins often display improved efficacy in vivo despite reduced specific activity (Nucci et al., 1991; Delgado et al., 1996; Eno-Amooquaye et al., 1996) .
Circulating life of glyco-sFv and PEG-glyco-sFv in mice
Groups of five mice were injected intravenously with unmodified CC49/218 sFv, EN280 glyco-sFv or PEGylated EN280 glyco-sFv and circulatory half-life, area under the curve (AUC) and mean residence time were calculated as described in Materials and methods. As shown in Figure 5 , the glyco-sFv displayed a very short serum half-life. The 2-fold faster elimination rate of the glyco-sFv (t 1/2 ϭ 0.39 Ϯ 0.01 h) when compared with the native sFv (t 1/2 ϭ 0.69 Ϯ 0.41 h) plausibly corresponds to clearance by mannose-receptor bearing cells such as macrophages. The PEGylated glyco-sFv circulating life is extended 10-fold (t 1/2 ϭ 3.84 Ϯ 0.46 h) when compared with the glyco-sFv (see Table II ).
Discussion
The importance of N-linked glycosylation in influencing the in vivo biodistribution and serum half-life, the proper folding and stability and the activity of glycoproteins has brought a resurgence in the field of glycotechnology (Jenkins et al., Fig. 5 . Pharmacokinetics of plasma retention of CC49/218 sFv, glyco-sFv and polyethylene glycol conjugate. Plasma retention studies of EN225 unmodified sFv (ϫ), EN280 glyco-sFv (j) and EN280 glyco-sFv conjugated to PEG-5000 (u) were performed in mice (five per group) as described in Materials and methods. 1996). Many unanswered questions about the fundamental biochemistry of N-glycan processing still remain. Although the N-X-T/S sequon is used for nearly all N-glycan attachments, the presence of this tripeptide on a secreted protein does not ensure even partial modification at that specific site, and successful glycosylations of engineered proteins have been achieved empirically (Gavel and von Heijne, 1990; Cregg et al., 1993; Jenkins et al., 1996) . Compilations of known Nlinked glycoproteins have led to two generalizations (Gavel and von Heijne, 1990) . First, N-linked glycans are very uncommon within a few residues of a polypeptide C-terminal residue. Second, tandem or overlapping N-glycan sites are very uncommon in glycoproteins. Our reported research partially breaks these 'rules' by achieving high-level secretion of fully active core-glycosylated or hyperglycosylated sFv proteins which have single or tandem N-glycan attachments 4-8 residues from the C-terminus. We speculate that outer chain α1-6 mannose elongation ('hypermannosylation') in the glycosFv tandem NXT variants may result from the kinetic effects of tandem N-glycan chain processing and/or an accompanying effect on the efficiency of the normal processing initiation and stop signals for outer chain elongation of the α1-6 mannose units (Herscovics and Orlean, 1993) . The optimal C-terminal location of the modification sites is fortuitous since the carboxyl terminus of the V L -linker-V H single chain Fv proteins is diametrically opposed to the antigen-binding site (see Figure  1A) . Indeed, numerous bifunctional sFv fusion proteins have been produced via a direct C-terminal linkage.
The successful construction of bioconjugates using sFv proteins and other therapeutic proteins which are attached to drug, polymer or effector molecules by random chemical linkages is often limited by a concomitant loss of binding affinity (e.g. Pettit et al., 1997) . The ability to secrete either core N-glycan modified sFv using a single N-X-T C-terminal site or hyperglycosylated sFv using a two-or three-site version was unexpected and provides much more versatility to the use of glyco-sFv in bioconjugate strategies. The potential uses of these glyco-sFv proteins in immunoconjugates may build upon the substantial foundation of carbohydrate-conjugated antibody/drug molecules presently in experimental and clinical trials (e.g. Rodwell et al., 1986; Leung et al., 1995) . Either minimal or extensive modifications of the glyco-sFv may be achieved depending on the length of the mannose chains. While we have shown a logarithmic increase in serum halflife of minimally PEGylated glyco-sFv, we have already achieved PEG:sFv ratios of Ͼ8 in active preparations of these conjugates and also expect that the use of longer PEG polymers will further extend serum half-life (Greenwald et al., 1996) . The circulating life of therapeutic single-chain Fv may ultimately be controllable by the choice of PEG-sFv bioconjugate.
The mannose-terminated sFv ('mannabodies') may also have interesting applications beyond bioconjugates. Considerable effort has been applied by several research groups in conjugating mannose to chemical and protein pharmaceuticals for specific targeting to mannose receptor bearing cells such as macrophages (Seymour, 1994) . We anticipate that the glycosFv from P.pastoris will display this targeting function, which may well correlate with the shortened mean residence time of these glycoproteins in serum. Furthermore, the targeting of foreign glyco-sFv to infected or cancerous cells might be employed clinically to provoke a hyperacute rejection response of the diseased tissue. Engineering P.pastoris to express glycosyltransferases from higher eukaryotes may ultimately provide further versatility. Additionally, the N-linked glycosylation designs described in this paper may have many applications in the selective (hyper)glycosylation of other therapeutic or diagnostic proteins. C-terminal tags, such as oligo(histidine) tails and other fusions, have proved to be of significant practical value in protein chemistry.
